KFS
KPTI icon

Kelly Financial Services’s Karyopharm Therapeutics KPTI Stock Holding History

Kelly Financial Services’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17
Closed -$217 – 464
2024
Q2 		$217 Hold
17
– – ﹤0.01% 738
2024
Q1 		$378 Hold
17
– – ﹤0.01% 737
2023
Q4 		$216 Hold
17
– – ﹤0.01% 735
2023
Q3 		$335 Hold
17
– – ﹤0.01% 710
2023
Q2 		$448 Hold
17
– – ﹤0.01% 659
2023
Q1 		$973 Hold
17
– – ﹤0.01% 596
2022
Q4 		$850 Hold
17
– – ﹤0.01% 578
2022
Q3 		$1.36K Hold
17
– – ﹤0.01% 545
2022
Q2 		$1.13K Hold
17
– – ﹤0.01% 544
2022
Q1 		$1.84K Hold
17
– – ﹤0.01% 525
2021
Q4 		$1.61K Hold
17
– – ﹤0.01% 566
2021
Q3 		$1.46K Sell
17
-155
-90% -$16.1K ﹤0.01% 552
2021
Q2 		$250K Buy
172
+155
+912% +$22.5K 0.01% 274
2021
Q1 		$2.63K Hold
17
– – ﹤0.01% 476
2020
Q4 		$3.87K Hold
17
– – ﹤0.01% 404
2020
Q3 		$3.65K Hold
17
– – ﹤0.01% 370
2020
Q2 		$4.74K Sell
17
-50
-75% -$14.8K ﹤0.01% 343
2020
Q1 		$19.4K Hold
67
– – 0.02% 136
2019
Q4 		$19.3K Hold
67
– – 0.01% 164
2019
Q3 		$9.7K Buy
+67
New +$9.08K 0.01% 229

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Kelly Financial Services's KPTI Position: Q3 2024 in Review

Kelly Financial Services sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 17 shares — an estimated $217 sold.

Kelly Financial Services first reported a position in KPTI in Q3 2019 and held it in 20 quarters. The position peaked at $250K in Q2 2021. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Kelly Financial Services reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Kelly Financial Services sold 17 Karyopharm Therapeutics shares in Q3 2024, an estimated $217.
  • Kelly Financial Services first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 20 quarters.
  • Kelly Financial Services's Karyopharm Therapeutics position peaked at $250K in Q2 2021.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.